Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy

Xinyan Li; Mozhi Wang; Mengshen Wang; Xueting Yu; Jingyi Guo; Tie Sun; Litong Yao; Qiang Zhang; Yingying Xu

추천

검색

자료유형: 학술저널

저자정보: Xinyan Li (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Mozhi Wang (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Mengshen Wang (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Xueting Yu (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Jingyi Guo (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Tie Sun (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Litong Yao (Department of Breast Surgery the First Affiliated Hospital of China Medical University Shenyang L) Qiang Zhang (Department of Breast Surgery Cancer Hospital of China Medical University Liaoning Cancer Hospital) Yingying Xu (Department of Breast Surgery the First Affiliated Hospital of China Medical University China)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.22 No.4

발행연도: 2019.1

수록면: 497 - 521 (25page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Currently, neoadjuvant chemotherapy is a standard therapeutic strategy for breast cancer, as it can provide timely and individualized chemo-sensitivity information and is beneficial for custom-designing subsequent treatment strategies. To accurately select candidates for neoadjuvant chemotherapy, the association between various immunohistochemical biomarkers of primary disease and tumor response to neoadjuvant chemotherapy has been investigated, and results have shown that certain pathological indicators evaluated after neoadjuvant chemotherapy are associated with long-term prognosis. The Food and Drug Administration (FDA) has recommended that complete pathological response can be used as a surrogate endpoint for neoadjuvant chemotherapy, which is related to better prognosis. Considering that residual tumor persists in the majority of patients after neoadjuvant chemotherapy, the value of various pathological indicators of residual disease in predicting the long-term outcomes is being extensively investigated. This review summarizes and compares various predictive and prognostic indicators for patients who have received neoadjuvant chemotherapy, and analyzes their efficacy in different breast cancer subtypes.

#Biomarkers #Breast neoplasms #Neoadjuvant therapy #Pathology #Survival

참고문헌 (118)

참고문헌 신청

Bray F / 2018 / Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / CA Cancer J Clin 68:394~424

Popat S / 2005 / Re : Neoadjuvant versus adjuvant systemic treatment in breast cancer : a meta-analysis / J Natl Cancer Inst 97:858

Kaufmann M / 2012 / Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer / Ann Surg Oncol 19:1508~1516

Viale G / 2013 / Characterization and clinical impact of residual disease after neoadjuvant chemotherapy / Breast 22(Suppl 2):S88~S91

Cortazar P / 2014 / Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis / Lancet 384:164~172

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!